Linda S. Barton - Concepedia

Author

Linda S. Barton

GlaxoSmithKline (United States)ORCID

Also Known As

Linda Barton, Linda S. Barton

Publications

389

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)South College Pathways Behavioral Services New Frontier

About

Linda S. Barton is an author at GlaxoSmithKline (United States) specializing in drug discovery, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	262
2	Biochemistry	3	3	220
3	Natural Sciences	2	2	162
4	Chemical Biology	1	1	90
5	Endocrinology	1	1	12

Linda S. Barton

Publications

380

Citations

H-Index

Page 1

	Year	Citations
Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide Thomas W. Ku, Fadia E. Ali, Linda S. Barton, Journal of the American Chemical Society Peptide EngineeringAltmetric Attention ScorePeptide SciencePeptide TherapeuticsChemical Biology	1993	90
Potent, Selective, Orally Active 3-Oxo-1,4-benzodiazepine GPIIb/IIIa Integrin Antagonists James M. Samanen, Fadia E. Ali, Linda S. Barton, Journal of Medicinal Chemistry Altmetric Attention ScorePharmacotherapyExperimental PharmacologyPharmacodynamic ModelingTranslational Pharmacology	1996	72
The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore David G. Washburn, Dennis A. Holt, Jason W. Dodson, Bioorganic & Medicinal Chemistry Letters Signal TransductionBiochemistryAnilino-thiazole PharmacophoreMedicineFunctional Selectivity	2013	58
Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4) Carl Brooks, Linda S. Barton, David J. Behm, ACS Medicinal Chemistry Letters	2019	51
Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics Richard M. Keenan, William H. Miller, Linda S. Barton, Bioorganic & Medicinal Chemistry Letters PharmacologyPharmacological AgentPharmacotherapyNon-peptide Ligand2-Aminopyridine Arginine Mimetics	1999	30
Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4) Edward J. Brnardic, Guosen Ye, Carl Brooks, Journal of Medicinal Chemistry	2018	27
Discovery of GSK3527497: A Candidate for the Inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4) Carl Brooks, Linda S. Barton, David J. Behm, Journal of Medicinal Chemistry	2019	23
Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library Technology in Combination with High-Throughput Screening Xinrong Tian, Dominic Suarez, Douglas W. Thomson, Journal of Medicinal Chemistry	2022	17
Improving the developability profile of pyrrolidine progesterone receptor partial agonists Lara S. Kallander, David G. Washburn, Tram H. Hoang, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyHormonal ContraceptiveMedicineHormonal ReceptorPhysiology	2009	12

Page 1